 After a Type C meeting with the FDA, Aptinyx Inc NASDAQ: APTX has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder PTSD. The program will consist of two separate studies to evaluate NYX-783 at two dose levels: 50 mg Study 1 and 150 mg Study 2. 